JP2022531719A5 - - Google Patents
Info
- Publication number
- JP2022531719A5 JP2022531719A5 JP2021566152A JP2021566152A JP2022531719A5 JP 2022531719 A5 JP2022531719 A5 JP 2022531719A5 JP 2021566152 A JP2021566152 A JP 2021566152A JP 2021566152 A JP2021566152 A JP 2021566152A JP 2022531719 A5 JP2022531719 A5 JP 2022531719A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- polypeptide
- domain
- cells
- items
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025179511A JP2026021386A (ja) | 2019-05-08 | 2025-10-24 | Ｃｄ３３標的免疫療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845304P | 2019-05-08 | 2019-05-08 | |
| US62/845,304 | 2019-05-08 | ||
| US201962898392P | 2019-09-10 | 2019-09-10 | |
| US62/898,392 | 2019-09-10 | ||
| PCT/US2020/031780 WO2020227474A1 (en) | 2019-05-08 | 2020-05-07 | Cd33 targeted immunotherapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025179511A Division JP2026021386A (ja) | 2019-05-08 | 2025-10-24 | Ｃｄ３３標的免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022531719A JP2022531719A (ja) | 2022-07-08 |
| JP2022531719A5 true JP2022531719A5 (enExample) | 2023-06-23 |
| JP7765291B2 JP7765291B2 (ja) | 2025-11-06 |
Family
ID=73050903
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566152A Active JP7765291B2 (ja) | 2019-05-08 | 2020-05-07 | Ｃｄ３３標的免疫療法 |
| JP2025179511A Pending JP2026021386A (ja) | 2019-05-08 | 2025-10-24 | Ｃｄ３３標的免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025179511A Pending JP2026021386A (ja) | 2019-05-08 | 2025-10-24 | Ｃｄ３３標的免疫療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12552855B2 (enExample) |
| EP (1) | EP3966251A4 (enExample) |
| JP (2) | JP7765291B2 (enExample) |
| KR (1) | KR20220031554A (enExample) |
| CN (1) | CN114206928B (enExample) |
| AU (1) | AU2020268379A1 (enExample) |
| BR (1) | BR112021022356A2 (enExample) |
| CA (1) | CA3139096A1 (enExample) |
| IL (1) | IL287770A (enExample) |
| MA (1) | MA55907A (enExample) |
| MX (1) | MX2021013591A (enExample) |
| SG (1) | SG11202111890RA (enExample) |
| WO (1) | WO2020227474A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020123947A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| CN116867806A (zh) * | 2021-02-10 | 2023-10-10 | 先声再明医药有限公司 | 人cd33抗体及其用途 |
| WO2023108158A2 (en) * | 2021-12-10 | 2023-06-15 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Methods and compositions for modulating the activity of a dimerizing agent regulated immunomodulatory complex |
| AU2023248532A1 (en) * | 2022-04-08 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Multipartite receptor and signaling complexes |
| KR20250007535A (ko) * | 2022-04-22 | 2025-01-14 | 인히브릭스 바이오사이언스, 인크. | Siglec-8 결합 단백질 및 그 용도 |
| WO2023230512A1 (en) | 2022-05-26 | 2023-11-30 | 2Seventy Bio, Inc. | Compositions for maintaining lentiviral vector and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100003253A1 (en) | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
| EP3027204B1 (en) | 2013-07-29 | 2022-01-05 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| WO2015142661A1 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
| ES2765710T3 (es) * | 2014-04-03 | 2020-06-10 | Cellectis | Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer |
| RS61406B1 (sr) * | 2014-06-06 | 2021-03-31 | Bluebird Bio Inc | Poboljšane kompozicije t ćelija |
| JP6831777B2 (ja) | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Ｃｄ３３キメラ抗原受容体を使用する癌の処置 |
| JP6894430B2 (ja) * | 2015-08-24 | 2021-06-30 | セレクティスＣｅｌｌｅｃｔｉｓ | 統合された制御機能を有するキメラ抗原受容体 |
| CA3048996A1 (en) | 2015-12-08 | 2017-06-15 | Regents Of The University Of Minnesota | Human t cell derived from t cell-derived induced pluripotent stem cell and methods of making and using |
| IL304871A (en) | 2016-01-11 | 2023-10-01 | Inhibrx Inc | Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses |
| US20190241910A1 (en) * | 2016-03-11 | 2019-08-08 | Bluebird Bio, Inc. | Genome edited immune effector cells |
| WO2017156479A1 (en) | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Ror1 chimeric antigen receptors |
| CN108884460B (zh) | 2016-03-19 | 2023-04-28 | 埃克苏马生物技术公司 | 淋巴细胞转导及其扩增调节的方法与组合物 |
| CA3020993A1 (en) | 2016-04-14 | 2017-10-19 | Bluebird Bio, Inc. | Salvage chimeric antigen receptor systems |
| AU2018240556B2 (en) | 2017-03-24 | 2025-02-27 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD33 immunotherapy |
| CN108659131B (zh) * | 2018-05-28 | 2021-09-14 | 长春力太生物技术有限公司 | 一种抗ceacam-5的单域抗体及其应用 |
| EP3966245A1 (en) * | 2019-05-04 | 2022-03-16 | Inhibrx, Inc. | Cd33-binding polypeptides and uses thereof |
-
2020
- 2020-05-07 CN CN202080048661.5A patent/CN114206928B/zh active Active
- 2020-05-07 JP JP2021566152A patent/JP7765291B2/ja active Active
- 2020-05-07 EP EP20802310.1A patent/EP3966251A4/en active Pending
- 2020-05-07 MX MX2021013591A patent/MX2021013591A/es unknown
- 2020-05-07 WO PCT/US2020/031780 patent/WO2020227474A1/en not_active Ceased
- 2020-05-07 SG SG11202111890RA patent/SG11202111890RA/en unknown
- 2020-05-07 AU AU2020268379A patent/AU2020268379A1/en active Pending
- 2020-05-07 US US17/608,743 patent/US12552855B2/en active Active
- 2020-05-07 CA CA3139096A patent/CA3139096A1/en active Pending
- 2020-05-07 BR BR112021022356A patent/BR112021022356A2/pt unknown
- 2020-05-07 KR KR1020217040150A patent/KR20220031554A/ko not_active Ceased
- 2020-05-07 MA MA055907A patent/MA55907A/fr unknown
-
2021
- 2021-11-01 IL IL287770A patent/IL287770A/en unknown
-
2025
- 2025-10-24 JP JP2025179511A patent/JP2026021386A/ja active Pending
-
2026
- 2026-01-12 US US19/445,942 patent/US20260132184A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022532556A5 (enExample) | ||
| JP7465306B2 (ja) | 免疫調節性融合タンパク質およびその使用 | |
| CN110760007B (zh) | Cd7-car-t细胞及其制备和应用 | |
| CN113784733B (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| JP7068459B2 (ja) | Ｎｙｅｓｏ ｔｃｒ | |
| AU2016228080B2 (en) | Reducing immune tolerance induced by PD-L1 | |
| CN111051502B (zh) | 通用型嵌合抗原受体t细胞制备技术 | |
| CN109593721B (zh) | 具有自杀基因开关的靶向人间皮素的工程化免疫细胞 | |
| CN118184800A (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| JP2025511872A5 (enExample) | ||
| EP3250695A1 (en) | Universal immune cells for cancer immunotherapy | |
| CA3119644A1 (en) | Chimeric antigen receptor factories and methods of use thereof | |
| EP2632482A2 (en) | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies | |
| JP2022537159A5 (enExample) | ||
| KR20230013257A (ko) | 종양 미세환경의 역전을 위한 융합 단백질 및 이의 응용 | |
| WO2019223226A1 (zh) | 改良型抗cd19 car-t细胞 | |
| CN110257338B (zh) | 嵌合细胞因子受体 | |
| KR20190096969A (ko) | 면역계를 조절하기 위한 조성물 및 방법 | |
| CN113840834B (zh) | Magea1特异性t细胞受体及其用途 | |
| Pircher et al. | T cell engineering | |
| CN113330038A (zh) | Cd20组合靶向的工程化免疫细胞 | |
| JP2020510074A5 (enExample) | ||
| CN117529505A (zh) | 设计为减少逆转录病毒重组的双顺反子嵌合抗原受体及其用途 | |
| KR20220038399A (ko) | 차용 면역치료법을 위한 조성물 및 방법 | |
| KR20240005865A (ko) | Prame 특이적 t 세포 수용체 및 키메라 공동 자극 수용체의 조합 |